BLACK DIAMOND THERAPEU

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

05 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

01 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

07 أكتوبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

23 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

22 سبتمبر 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

14 سبتمبر 2024 03:30:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

06 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

01 يونيو 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

29 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Changes to Board of Directors

11 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

07 أبريل 2024 18:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

03 أبريل 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

12 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

05 مارس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

04 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

13 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

07 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire